vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $260.4M, roughly 1.3× Smith Douglas Homes Corp.). HAEMONETICS CORP runs the higher net margin — 13.2% vs 1.4%, a 11.8% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -9.4%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $8.7M). Over the past eight quarters, Smith Douglas Homes Corp.'s revenue compounded faster (17.3% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
HAE vs SDHC — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $260.4M |
| Net Profit | $44.7M | $3.5M |
| Gross Margin | 59.7% | 19.9% |
| Operating Margin | 19.9% | 6.5% |
| Net Margin | 13.2% | 1.4% |
| Revenue YoY | -2.7% | -9.4% |
| Net Profit YoY | 19.3% | -14.3% |
| EPS (diluted) | $0.95 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $260.4M | ||
| Q3 25 | $327.3M | $262.0M | ||
| Q2 25 | $321.4M | $223.9M | ||
| Q1 25 | $330.6M | $224.7M | ||
| Q4 24 | $348.5M | $287.5M | ||
| Q3 24 | $345.5M | $277.8M | ||
| Q2 24 | $336.2M | $220.9M | ||
| Q1 24 | — | $189.2M |
| Q4 25 | $44.7M | $3.5M | ||
| Q3 25 | $38.7M | $2.1M | ||
| Q2 25 | $34.0M | $2.4M | ||
| Q1 25 | $58.0M | $2.7M | ||
| Q4 24 | $37.5M | $4.1M | ||
| Q3 24 | $33.8M | $5.3M | ||
| Q2 24 | $38.4M | $3.6M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | 59.7% | 19.9% | ||
| Q3 25 | 59.5% | 21.0% | ||
| Q2 25 | 59.8% | 23.2% | ||
| Q1 25 | 58.4% | 23.8% | ||
| Q4 24 | 55.5% | 25.5% | ||
| Q3 24 | 54.2% | 26.5% | ||
| Q2 24 | 52.0% | 26.7% | ||
| Q1 24 | — | 26.1% |
| Q4 25 | 19.9% | 6.5% | ||
| Q3 25 | 17.9% | 6.6% | ||
| Q2 25 | 16.8% | 7.7% | ||
| Q1 25 | 21.6% | 8.7% | ||
| Q4 24 | 16.9% | 10.4% | ||
| Q3 24 | 15.0% | 14.2% | ||
| Q2 24 | 11.8% | 11.7% | ||
| Q1 24 | — | 11.3% |
| Q4 25 | 13.2% | 1.4% | ||
| Q3 25 | 11.8% | 0.8% | ||
| Q2 25 | 10.6% | 1.1% | ||
| Q1 25 | 17.5% | 1.2% | ||
| Q4 24 | 10.8% | 1.4% | ||
| Q3 24 | 9.8% | 1.9% | ||
| Q2 24 | 11.4% | 1.7% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | $0.95 | $0.39 | ||
| Q3 25 | $0.81 | $0.24 | ||
| Q2 25 | $0.70 | $0.26 | ||
| Q1 25 | $1.17 | $0.30 | ||
| Q4 24 | $0.74 | $0.50 | ||
| Q3 24 | $0.66 | $0.58 | ||
| Q2 24 | $0.74 | $0.40 | ||
| Q1 24 | — | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $12.7M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $86.7M |
| Total Assets | $2.5B | $557.6M |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $12.7M | ||
| Q3 25 | $296.4M | $14.8M | ||
| Q2 25 | $292.9M | $16.8M | ||
| Q1 25 | $306.8M | $12.7M | ||
| Q4 24 | $320.8M | $22.4M | ||
| Q3 24 | $299.3M | $23.7M | ||
| Q2 24 | $344.4M | $17.3M | ||
| Q1 24 | — | $32.8M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $86.7M | ||
| Q3 25 | $849.2M | $82.2M | ||
| Q2 25 | $882.3M | $80.0M | ||
| Q1 25 | $820.8M | $76.9M | ||
| Q4 24 | $906.9M | $73.6M | ||
| Q3 24 | $878.9M | $68.4M | ||
| Q2 24 | $905.4M | $62.1M | ||
| Q1 24 | — | $59.7M |
| Q4 25 | $2.5B | $557.6M | ||
| Q3 25 | $2.4B | $571.6M | ||
| Q2 25 | $2.5B | $570.2M | ||
| Q1 25 | $2.5B | $513.9M | ||
| Q4 24 | $2.5B | $475.9M | ||
| Q3 24 | $2.5B | $460.1M | ||
| Q2 24 | $2.5B | $429.3M | ||
| Q1 24 | — | $401.3M |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $9.8M |
| Free Cash FlowOCF − Capex | $87.2M | $8.7M |
| FCF MarginFCF / Revenue | 25.7% | 3.4% |
| Capex IntensityCapex / Revenue | 1.9% | 0.4% |
| Cash ConversionOCF / Net Profit | 2.09× | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $9.8M | ||
| Q3 25 | $111.3M | $22.8M | ||
| Q2 25 | $17.4M | $-28.9M | ||
| Q1 25 | $116.6M | $-34.9M | ||
| Q4 24 | $43.8M | $5.5M | ||
| Q3 24 | $48.8M | $22.9M | ||
| Q2 24 | $-27.4M | $39.0K | ||
| Q1 24 | — | $-9.3M |
| Q4 25 | $87.2M | $8.7M | ||
| Q3 25 | $106.3M | $21.4M | ||
| Q2 25 | $13.6M | $-31.1M | ||
| Q1 25 | $100.9M | $-35.9M | ||
| Q4 24 | $35.2M | $4.8M | ||
| Q3 24 | $39.4M | $22.3M | ||
| Q2 24 | $-33.1M | $-2.1M | ||
| Q1 24 | — | $-9.7M |
| Q4 25 | 25.7% | 3.4% | ||
| Q3 25 | 32.5% | 8.2% | ||
| Q2 25 | 4.2% | -13.9% | ||
| Q1 25 | 30.5% | -16.0% | ||
| Q4 24 | 10.1% | 1.7% | ||
| Q3 24 | 11.4% | 8.0% | ||
| Q2 24 | -9.8% | -1.0% | ||
| Q1 24 | — | -5.1% |
| Q4 25 | 1.9% | 0.4% | ||
| Q3 25 | 1.5% | 0.5% | ||
| Q2 25 | 1.2% | 0.9% | ||
| Q1 25 | 4.7% | 0.5% | ||
| Q4 24 | 2.5% | 0.2% | ||
| Q3 24 | 2.7% | 0.2% | ||
| Q2 24 | 1.7% | 1.0% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | 2.09× | 2.77× | ||
| Q3 25 | 2.88× | 10.70× | ||
| Q2 25 | 0.51× | -12.24× | ||
| Q1 25 | 2.01× | -13.01× | ||
| Q4 24 | 1.17× | 1.33× | ||
| Q3 24 | 1.44× | 4.28× | ||
| Q2 24 | -0.71× | 0.01× | ||
| Q1 24 | — | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
